Johnson & Johnson (JNJ) posted a full-year revenue increase of 11.3%, reaching $93.5 billion for fiscal 2025. This marks the first time since 2021 that the company has delivered double-digit top-line growth, driven primarily by a 9.8% rise in its medical devices segment and a 12.7% gain in consumer health. JNJ’s adjusted EPS climbed 14.1% to $10.42. Management now targets revenue growth of 8–12% and an EPS increase of 10–14% in 2026, underpinned by operational efficiencies and ongoing cost-optimization measures that yielded $1.2 billion in savings last year.

JNJ’s oncology franchise delivered standout performance, with sales up 15.2% to $6.2 billion in 2025. Key growth drivers included Darzalex® (daratumumab) and Imbruvica® (ibrutinib), which together contributed $3.8 billion in revenue. The late-stage pipeline features five new oncology indications—including two CAR-T cell therapies slated for FDA review in 2026—projected to add $3 billion in annual sales by 2028. Analysts at Barclays forecast a 10% compound annual growth rate for JNJ’s oncology revenues through 2028, highlighting therapeutic area expansion in multiple myeloma and chronic lymphocytic leukemia as critical catalysts.